Department of Cardiothoracic & Vascular Surgery, Advanced Aortic Research Program at the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX.
Medical University of Warsaw, Warszawa, Poland.
Ann Surg. 2023 Oct 1;278(4):568-577. doi: 10.1097/SLA.0000000000005986. Epub 2023 Jul 3.
To describe outcomes after elective and non-elective fenestrated-branched endovascular aortic repair (FB-EVAR) for thoracoabdominal aortic aneurysms (TAAAs).
FB-EVAR has been increasingly utilized to treat TAAAs; however, outcomes after non-elective versus elective repair are not well described.
Clinical data of consecutive patients undergoing FB-EVAR for TAAAs at 24 centers (2006-2021) were reviewed. Endpoints including early mortality and major adverse events (MAEs), all-cause mortality, and aortic-related mortality (ARM), were analyzed and compared in patients who had non-elective versus elective repair.
A total of 2603 patients (69% males; mean age 72±10 year old) underwent FB-EVAR for TAAAs. Elective repair was performed in 2187 patients (84%) and non-elective repair in 416 patients [16%; 268 (64%) symptomatic, 148 (36%) ruptured]. Non-elective FB-EVAR was associated with higher early mortality (17% vs 5%, P <0.001) and rates of MAEs (34% vs 20%, P <0.001). Median follow-up was 15 months (interquartile range, 7-37 months). Survival and cumulative incidence of ARM at 3 years were both lower for non-elective versus elective patients (50±4% vs 70±1% and 21±3% vs 7±1%, P <0.001). On multivariable analysis, non-elective repair was associated with increased risk of all-cause mortality (hazard ratio, 1.92; 95% CI] 1.50-2.44; P <0.001) and ARM (hazard ratio, 2.43; 95% CI, 1.63-3.62; P <0.001).
Non-elective FB-EVAR of symptomatic or ruptured TAAAs is feasible, but carries higher incidence of early MAEs and increased all-cause mortality and ARM than elective repair. Long-term follow-up is warranted to justify the treatment.
描述择期和非择期开窗分支型腔内血管修复术(FB-EVAR)治疗胸腹主动脉瘤(TAAA)的结果。
FB-EVAR 已越来越多地用于治疗 TAAA;然而,择期与非择期修复的结果描述并不完善。
回顾了 24 个中心(2006-2021 年)连续接受 FB-EVAR 治疗 TAAA 的患者的临床数据。分析并比较了择期和非择期修复的患者的早期死亡率和主要不良事件(MAE)、全因死亡率和主动脉相关死亡率(ARM)等终点。
共 2603 例患者(69%为男性;平均年龄 72±10 岁)接受 FB-EVAR 治疗 TAAA。2187 例患者(84%)行择期修复,416 例患者(16%;268 例为症状性,148 例为破裂性)行非择期修复。非择期 FB-EVAR 早期死亡率(17%比 5%,P <0.001)和 MAE 发生率(34%比 20%,P <0.001)更高。中位随访时间为 15 个月(四分位距,7-37 个月)。非择期与择期患者 3 年生存率和 ARM 累积发生率均较低(50±4%比 70±1%和 21±3%比 7±1%,P <0.001)。多变量分析显示,非择期修复与全因死亡率(危险比,1.92;95%CI 1.50-2.44;P <0.001)和 ARM(危险比,2.43;95%CI 1.63-3.62;P <0.001)风险增加相关。
对症状性或破裂性 TAAA 进行非择期 FB-EVAR 是可行的,但与择期修复相比,早期 MAE 发生率更高,全因死亡率和 ARM 更高。需要进行长期随访以证明治疗的合理性。